Please Wait
Applying Filters...
menu
    • menu
    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Sharp is a global leader in pharmaceutical packaging and clinical trial supply services.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Lonapegsomatropin

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    New InsiGHTS Trial of TransCon™ hGH Achieves Primary Goal
    New InsiGHTS Trial of TransCon™ hGH Achieves Primary Goal

    16 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/16/2997524/0/en/New-InsiGHTS-Trial-of-TransCon-hGH-Lonapegsomatropin-in-Turner-Syndrome-Achieved-Primary-Objective-at-Week-26.html

    GLOBENEWSWIRE
    16 Dec 2024
    Share Share
    Vector Pharma FZCO Announce Agreement with Ascendis for Skytrofa
    Vector Pharma FZCO Announce Agreement with Ascendis for Skytrofa

    08 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/01/08/2805433/0/en/Vector-Pharma-FZCO-Announce-Exclusive-Distribution-Agreement-with-Ascendis-Pharma-A-S-for-Skytrofa-lonapegsomatropin-and-Yorvipath-palopegteriparatide-in-Gulf-Cooperation-Council-C.html

    GLOBENEWSWIRE
    08 Jan 2024
    Share Share
    TransCon Achieved Superior Outcomes Compared to Placebo in Ph 3 foresiGHt Trial
    TransCon Achieved Superior Outcomes Compared to Placebo in Ph 3 foresiGHt Trial

    19 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/12/19/2798534/0/en/TransCon-hGH-lonapegsomatropin-Achieved-Statistically-Superior-Outcomes-Compared-to-Placebo-in-Phase-3-foresiGHt-Trial-of-Adults-with-Growth-Hormone-Deficiency.html

    GLOBENEWSWIRE
    19 Dec 2023
    Share Share
    Ascendis Pharma Launches SKYTROFA in Germany
    Ascendis Pharma Launches SKYTROFA in Germany

    15 Sep 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/09/15/2743952/0/en/Ascendis-Pharma-Launches-SKYTROFA-lonapegsomatropin-in-Germany-for-the-Once-Weekly-Treatment-of-Children-and-Adolescents-with-Growth-Hormone-Deficiency.html

    GLOBENEWSWIRE
    15 Sep 2023
    Share Share
    Ascendis' Biologic Skytrofa (Lonapegsomatropin) Receives Approval in the U.S.
    Ascendis' Biologic Skytrofa (Lonapegsomatropin) Receives Approval in the U.S.

    20 Oct 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761177

    FDA
    20 Oct 2022
    Share Share
    VISEN Pharma's Top-line Results of PIII Trial of Once-Weekly Lonapegsomatropin
    VISEN Pharma's Top-line Results of PIII Trial of Once-Weekly Lonapegsomatropin

    23 May 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/visen-pharmaceuticals-announces-top-line-results-of-phase-3-trial-of-once-weekly-lonapegsomatropin-demonstrating-superior-efficacy-comparable-safety-and-tolerability-to-daily-growth-hormone-301552704.html

    PRNEWSWIRE
    23 May 2022
    Share Share